Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0495
Trial ID NCT04008251
Disease B-Cell Lymphoma | Acute Lymphoblastic Leukemia
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
Co-treatment Tocilizumab
Generation2nd
PhasePhase1
Recruitment statusUnknown
TitleHumanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Year2019
CountryChina
Company sponsorWuhan Sian Medical Technology Co., Ltd
Other ID(s)CART-huCD19-01
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted genehumanized CD19 single chain variable fragment (scFv); CD137 costimulatory domain

Clinical Result

Cohort1: Tocilizumab
Administration route None
Dosage 2~4E6 cells/kg
Pts 32
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome Of the total 67 patients, 86.6% (N=58) responded and 85% (N=57) achieved complete remission with MRD and genotype negativity.
References PMID: 35799791
Cohort2: no Tocilizumab
Administration route None
Dosage 2~6E6 cells/kg
Pts 35
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome Of the total 67 patients, 86.6% (N=58) responded and 85% (N=57) achieved complete remission with MRD and genotype negativity.
References PMID: 35799791

Relationship Graph

Overview of Knowledge Graph